(Q48219239)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28217871%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

title

Secukinumab in Active Rheumatoid Arthritis: A Phase III Randomized, Double-Blind, Active Comparator- and Placebo-Controlled Study (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28217871%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

1 reference

1 reference

Francisco J Blanco Garcia

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28217871%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

author name string

Rüdiger Möricke

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28217871%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

Eva Dokoupilova

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28217871%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

Christine Codding

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28217871%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

Jeffrey Neal

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28217871%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

Mats Andersson

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28217871%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

Susanne Rohrer

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28217871%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

Hanno Richards

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28217871%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

publication date

3 May 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28217871%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

published in

Arthritis & Rheumatology

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28217871%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

volume

69

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28217871%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28217871%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

page(s)

1144-1153

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28217871%20AND%20SRC:MED&resulttype=core&format=json

The pathogenesis of rheumatoid arthritis

3 April 2020

cites work

1 reference

Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases.

21 January 2018

1 reference

The burden of disease in rheumatoid arthritis

21 January 2018

1 reference

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update

21 January 2018

1 reference

The therapeutic potential of costimulatory blockade with CTLA4Ig in rheumatoid arthritis

21 January 2018

1 reference

Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion

21 January 2018

1 reference

Effects of AIN457, a Fully Human Antibody to Interleukin-17A, on Psoriasis, Rheumatoid Arthritis, and Uveitis

21 January 2018

1 reference

Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study

21 January 2018

1 reference

One-year efficacy and safety results of secukinumab in patients with rheumatoid arthritis: phase II, dose-finding, double-blind, randomized, placebo-controlled study

21 January 2018

1 reference

A phase II randomized study of subcutaneous ixekizumab, an anti-interleukin-17 monoclonal antibody, in rheumatoid arthritis patients who were naive to biologic agents or had an inadequate response to tumor necrosis factor inhibitors

21 January 2018

1 reference

IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis

21 January 2018

1 reference

Heterogeneous expression pattern of interleukin 17A (IL-17A), IL-17F and their receptors in synovium of rheumatoid arthritis, psoriatic arthritis and osteoarthritis: possible explanation for nonresponse to anti-IL-17 therapy?

21 January 2018

1 reference

IL-17 as a future therapeutic target for rheumatoid arthritis

21 January 2018

1 reference

Efficacy and Safety of Subcutaneous and Intravenous Loading Dose Regimens of Secukinumab in Patients with Active Rheumatoid Arthritis: Results from a Randomized Phase II Study

21 January 2018

1 reference

Association of HLA-DRB1 alleles with clinical responses to the anti-interleukin-17A monoclonal antibody secukinumab in active rheumatoid arthritis

21 January 2018

1 reference

2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative

21 January 2018

1 reference

American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis

21 January 2018

1 reference

Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis

21 January 2018

1 reference

Measurement of patient outcome in arthritis

21 January 2018

1 reference

Safety and Efficacy of Open-label Subcutaneous Ixekizumab Treatment for 48 Weeks in a Phase II Study in Biologic-naive and TNF-IR Patients with Rheumatoid Arthritis

21 January 2018

1 reference

Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study

21 January 2018

1 reference

Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks

21 January 2018

1 reference

Comparative effects of biologics on cardiovascular risk among older patients with rheumatoid arthritis

21 January 2018

1 reference

Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/ART.40070

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28217871%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

1 reference